ECSP22087539A - Inhibidores de kras tricíclicos fusionados - Google Patents

Inhibidores de kras tricíclicos fusionados

Info

Publication number
ECSP22087539A
ECSP22087539A ECSENADI202287539A ECDI202287539A ECSP22087539A EC SP22087539 A ECSP22087539 A EC SP22087539A EC SENADI202287539 A ECSENADI202287539 A EC SENADI202287539A EC DI202287539 A ECDI202287539 A EC DI202287539A EC SP22087539 A ECSP22087539 A EC SP22087539A
Authority
EC
Ecuador
Prior art keywords
fusioned
tricyclic
compounds
kras inhibitors
kras
Prior art date
Application number
ECSENADI202287539A
Other languages
English (en)
Inventor
Artem Shvartsbart
Chao Qi
Wenyu Zhu
xiaozhao Wang
Wenqing Yao
Rocco Policarpo
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of ECSP22087539A publication Critical patent/ECSP22087539A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen compuestos de la fórmula I, métodos de uso de compuestos para inhibir la actividad de KRAS y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de KRAS, como el cáncer.
ECSENADI202287539A 2020-04-16 2022-11-15 Inhibidores de kras tricíclicos fusionados ECSP22087539A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011089P 2020-04-16 2020-04-16
US202163146899P 2021-02-08 2021-02-08

Publications (1)

Publication Number Publication Date
ECSP22087539A true ECSP22087539A (es) 2023-01-31

Family

ID=75870725

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202287539A ECSP22087539A (es) 2020-04-16 2022-11-15 Inhibidores de kras tricíclicos fusionados

Country Status (16)

Country Link
US (1) US20210355121A1 (es)
EP (1) EP4135844A1 (es)
JP (1) JP2023522202A (es)
CN (1) CN115702025A (es)
AU (1) AU2021254794A1 (es)
BR (1) BR112022020841A2 (es)
CA (1) CA3179692A1 (es)
CL (2) CL2022002828A1 (es)
CO (1) CO2022016377A2 (es)
CR (1) CR20220584A (es)
EC (1) ECSP22087539A (es)
IL (1) IL297165A (es)
MX (1) MX2022012780A (es)
PE (1) PE20230825A1 (es)
TW (1) TW202204355A (es)
WO (1) WO2021211864A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
EP4021444A4 (en) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. G12D KRAS INHIBITORS
CN114761012A (zh) 2019-09-24 2022-07-15 米拉蒂治疗股份有限公司 组合疗法
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AU2022270116A1 (en) 2021-05-05 2023-12-21 Revolution Medicines, Inc. Ras inhibitors
CA3234375A1 (en) * 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
IL312114A (en) * 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
US20230226040A1 (en) 2021-11-22 2023-07-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
CN115317490A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 化合物bml-275在制备改善鼻咽癌预后的药物中的应用
CN114394967B (zh) * 2022-01-28 2023-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种2-吡唑苯胺与1,3-二羰基化合物合成吡唑并喹啉衍生物的方法
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US20240101557A1 (en) * 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0111747A (pt) 2000-06-28 2003-07-08 Smithkline Beecham Plc Processo de moagem úmida
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
DK1470124T3 (da) 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
CA2586605A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP3118203B1 (en) 2010-10-25 2018-10-24 G1 Therapeutics, Inc. Cdk inhibitors
CN102655637A (zh) * 2011-03-01 2012-09-05 中兴通讯股份有限公司 一种移动通信系统和组网方法
KR20160035613A (ko) 2011-03-23 2016-03-31 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
CN103930423B (zh) * 2011-10-07 2015-09-16 卫材Rd管理有限公司 吡唑并喹啉衍生物
EP3277678B1 (en) * 2015-04-03 2020-03-18 NantBio, Inc. Compositions and methods of targeting mutant k-ras
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US10414757B2 (en) * 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
CA3047980A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
MX2019007416A (es) 2016-12-22 2019-12-11 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
JP7372255B2 (ja) 2018-03-30 2023-10-31 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
SG11202010463TA (en) * 2018-04-25 2020-11-27 Innate Tumor Immunity Inc Nlrp3 modulators
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
EP3837014B1 (en) * 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators

Also Published As

Publication number Publication date
CO2022016377A2 (es) 2023-02-27
EP4135844A1 (en) 2023-02-22
CN115702025A (zh) 2023-02-14
CA3179692A1 (en) 2021-10-21
PE20230825A1 (es) 2023-05-19
WO2021211864A1 (en) 2021-10-21
CR20220584A (es) 2023-02-15
MX2022012780A (es) 2023-01-18
US20210355121A1 (en) 2021-11-18
JP2023522202A (ja) 2023-05-29
AU2021254794A1 (en) 2022-12-15
IL297165A (en) 2022-12-01
TW202204355A (zh) 2022-02-01
CL2023002090A1 (es) 2023-12-15
BR112022020841A2 (pt) 2023-05-02
CL2022002828A1 (es) 2023-03-31

Similar Documents

Publication Publication Date Title
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CO2020015437A2 (es) Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
DOP2021000154A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
BR112021018303A2 (pt) Novos inibidores de pequenas moléculas de fatores de transcrição tead
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
GT201000172A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
UY39477A (es) Compuestos espiro heterocíclicos y métodos de uso
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CO2022018636A2 (es) Moduladores de il-17a
CO2022016899A2 (es) Moduladores de il-17a
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
ECSP21044843A (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CO2023008475A2 (es) Inhibidores de enzimas
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos
CO2024000832A2 (es) Inhibidores de transglutaminasas